Milacemide
From Wikipedia, the free encyclopedia
| Milacemide | |
|---|---|
 |
|
|
N2-Pentylglycinamide[citation needed] |
|
|
2-(Pentylamino)acetamide[1] |
|
| Identifiers | |
| CAS number | 76990-56-2  |
| PubChem | 53569 |
| ChemSpider | 48376 |
| UNII | 0HXT24RECU |
| MeSH | milacemide |
| ChEMBL | CHEMBL75838 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C7H16N2O |
| Molar mass | 144.21 g mol−1 |
| Exact mass | 144.126263144 g mol−1 |
| log P | 0.754 |
| Related compounds | |
| Related compounds | Tricine |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references |
Milacemide is a MAO-B inhibitor and glycine prodrug.[2] It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.[3] Early clinical trials, however, showed no positive results.[2]
[edit] References
- ^ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53569&loc=ec_rcs. Retrieved 9 January 2012.
- ^ a b Dysken, MW; Mendels, J, LeWitt, P, Reisberg, B, Pomara, N, Wood, J, Skare, S, Fakouhi, JD, Herting, RL (1992 May). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.". Journal of the American Geriatrics Society 40 (5): 503–6. PMID 1634705. http://www.ncbi.nlm.nih.gov/pubmed/1634705.
- ^ Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed. ed.). New York, NY: Facts on File. ISBN 081604774X. http://www.scribd.com/doc/10098801/The-Encyclopedia-of-the-Brain-and-Brain-Disorders.
|
